Quantcast
Home > Quotes > CALA
CALA

Calithera Biosciences, Inc. Common Stock (CALA) Quote & Summary Data

$5.03
*  
0.19
3.93%
Get CALA Alerts
*Delayed - data as of Nov. 12, 2018  -  Find a broker to begin trading CALA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5 / $ 5.15
1 Year Target
15
Today's High / Low
$ 5.15 / $ 4.70
Share Volume
897,403
50 Day Avg. Daily Volume
364,803
Previous Close
$ 4.84
52 Week High / Low
$ 16.50 / $ 4.05
Market Cap
191,772,351
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.29
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.02

Intraday Chart

Shares Traded

Share Volume:
897,403
50 Day Avg. Daily Volume:
364,803

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.29

Trading Range

The current last sale of $5.03 is 24.20% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.15 $ 16.50
 Low: $ 4.70 $ 4.05

Company Description (as filed with the SEC)

We are a clinical-stage bio-pharmaceutical company focused on fighting cancer by discovering and developing novel small molecule oncology drugs that target tumor and immune cell metabolism. Tumor metabolism and immuno-oncology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. With our unique oncometabolism approach, we have discovered two small molecule drug candidates that are currently in clinical development. These agents take advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells. Our lead product candidate, CB-839, is an internally discovered, first-in-class oral inhibitor of glutaminase, a critical enzyme in tumor cells. Our strategy is to develop CB-839 as combination therapy with approved agents, in order to improve the treatment of patients with cancer.  ... More ...  


Risk Grade

Where does CALA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.85
Open Date:
Nov. 12, 2018
Close Price:
$ 4.84
Close Date:
Nov. 9, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x